Symbols

WHWK

Whitehawk·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About WHWK

Whitehawk Therapeutics, Inc.

A biopharmaceutical company focused on precision therapies for genetically defined cancers with alterations in mTOR pathway genes

Industry

Pharmaceutical

Established Date

11/16/2007

Listing Date

06/26/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.whitehawktx.com

Security Type

Common stock

Office address

2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey 07960

Business

Introduction

Whitehawk Therapeutics, Inc., was incorporated in Delaware on November 16, 2007. The company is a clinical-stage biopharmaceutical company developing precision therapies for genetically defined cancers. The company's main goal is to bring translational therapies to cancer patients with changes in mTOR pathway drivers, such as changes in the TSC1 or TSC2 genes, while mTOR inhibitors are not or cannot be effectively utilized due to pharmacological, effective drug delivery, safety or efficacy issues. Aadi's main product is FYARROTM, an mTOR inhibitor that binds to human proteins and shows higher tumor accumulation, greater mTOR target inhibition and enhanced tumor growth inhibition.

Company Financials

EPS

WHWK has released its 2025 Q3 earnings. EPS was reported at -0.26, versus the expected -0.22, missing expectations. The chart below visualizes how WHWK has performed over recent quarters, highlighting trends in earnings surprises.